Patients with prostate cancer from sexual minority groups experience considerably worse quality of life following prostate cancer treatment than heterosexual patients. Improved inclusivity as well as cultural humility training at the physician, institution and system levels are warranted to address inequalities in quality-of-life outcomes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Rosser, B. R. S. et al. Understanding prostate cancer in gay, bisexual, and other men who have sex with men and transgender women: a review of the literature. Curr. Sex. Health Rep. 11, 430–441 (2019).
Rosser, B. R. S. et al. Health disparities of sexual minority patients following prostate cancer treatment: results from the Restore-2 study. Front. Oncol. 12, 812117 (2022).
Ussher, J. M. et al. Health-related quality of life, psychological distress, and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men. J. Sex. Med. 13, 425–434 (2016).
Haggart, R. et al. Comorbidity prevalence and impact on quality of life in gay and bisexual men following prostate cancer treatment. Sex. Med. 9, 100439 (2021).
McInnis, M. K. & Pukall, C. F. Sex after prostate cancer in gay and bisexual men: a review of the literature. Sex. Med. Rev. 8, 466–472 (2020).
Polter, E. J. et al. Creation and psychometric validation of the sexual minorities and prostate cancer scale (SMACS) in sexual minority patients-the Restore-2 study. J. Sex. Med. 19, 529–540 (2022).
Lee, T. K. et al. Development of a sexual quality of life questionnaire for men-who-have-sex-with-men with prostate cancer. Sex. Med. 10, 100480 (2022).
Alpert, A. et al. What exactly are we measuring? Evaluating sexual and gender minority cultural humility training for oncology care clinicians. J. Clin. Oncol. 38, 2605–2609 (2020).
Berrahou, I. K., Snow, A., Swanson, M. & Obedin-Maliver, J. Representation of sexual and gender minority people in patient nondiscrimination policies of cancer centers in the United States. J. Natl Compr. Cancer Netw. https://doi.org/10.6004/jnccn.2021.7078 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.R. declares stock and other ownership interests: ECOM Medical; consulting or advisory role: Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics and Gilead Sciences; speakers’ bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences and AVEO; research funding: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics and Epizyme; and travel, accommodations and/or expenses: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis and AstraZeneca. D.J.B. declares no competing interests.
Rights and permissions
About this article
Cite this article
Benjamin, D.J., Rezazadeh, A. Quality of life in sexual minorities following prostate cancer treatment. Nat Rev Urol 19, 323–324 (2022). https://doi.org/10.1038/s41585-022-00601-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-022-00601-5